|
|
 |
Your Online Resource for Diabetes Treatment
Home > Literature
Alerts > Recent Articles
Updated September, 07 2009
Recent Diabetes Articles | 
|
| • |
The role of pioglitazone in modifying the atherogenic lipoprotein profile
Hanefeld M
Diabetes, Obesity and Metabolism. 2009;11(8):742-756 |
| • |
The Cardiovascular Effects of Metformin: Further Reasons to Consider an Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Anfossi G, Russo I, Bonomo K, Trovati M
ACC Abstracts of the 48th Scientific Session. 2010 Jan 1. [Epub ahead of print] |
| • |
Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers
Kalaitzidis R, Bakris G
Diabetes, Obesity and Metabolism. 2009;11(8):757-769 |
| • |
Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes
Aso Y, Hara K, Ozeki N, et al
Diabetes Res Clin Pract. 2009;85(2):147-152 |
| • |
Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus
Kanazu S, Horie Y, Narukawa M, et al
Diabetes, Obesity and Metabolism. 2009;11(8):813-818 |
| • |
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial
Schweizer A, Dejager S, Bosi E
Diabetes, Obesity and Metabolism. 2009;11(8):804-812 |
| • |
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Hansen KB, Knop FK, Holst JJ, Vilsbøll T
Int J Clin Pract. 2009;63(8):1154-1160 |
| • |
Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers
Abbasi F, Lamendola C, Leary ET, Reaven GM
Diabetes, Obesity and Metabolism. 2009;11(8):779-785 |
| • |
Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus
Ai M, Otokozawa S, Schaefer EJ, et al
Clin Chimica Acta.. 2009;406(1-2):71-74 |
| • |
Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies
Ruchat SM, Elks CE, Loos RJ, et al
Acta Diabetol. 2009;46(3):217-226 |
| • |
Prevalence of diagnosed and undiagnosed diabetes mellitus and impaired fasting glucose in Sardinia
Muntoni S, Atzori L, Mereu R, et al
Acta Diabetol. 2009;46(3):227-231 |
| • |
Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus
Galvano F, Li Volti G, Malaguarnera M, et al
Expert Opin Pharmacother. 2009;10(12):1875-1882 |
| • |
Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes
Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B
Diabetes Care. 2009;32(8):1513-1517 |
| • |
Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects
Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA
Curr Med Res Opin. 2009;25(8):1963-1972 |
| • |
Blood pressure variables and cardiovascular risk: new findings from ADVANCE
Kengne AP, Czernichow S, Huxley R, et al, for the ADVANCE Collaborative Group
Hypertension. 2009;54(2):399-404 |
| • |
Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes
Gatti A, Maranghi M, Bacci S, et al
Diabetes Care. 2009;32(8):1550-1552 |
| • |
Differences in atherosclerotic plaque burden and morphology between type 1 and 2 diabetes as assessed by multislice computed tomography
Djaberi R, Schuijf JD, Boersma E, et al
Diabetes Care. 2009;32(8):1507-1512 |
| • |
Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia
Pruski M, Krysiak R, Okopien B
Diabetes Care. 2009;32(8):1421-1424 |
| • |
The pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia
Pruski M, Krysiak R, Okopien B
Diabetes Care. 2009 May 12. [Epub ahead of print] |
| • |
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Buse JB, Rosenstock J, Sesti G, et al for the LEAD-6 Study Group
Lancet. 2009;374(9683):39-47 |
| • |
Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus
Harashima K, Hayashi J, Miwa T, Tsunoda T
Metabolism. 2009;58(6):739-745 |
| • |
Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes
Kazempour-Ardebili S, Lecamwasam VL, et al
Diabetes Care. 2009;32(7):1137-1142 |
| • |
Cognition in the early stage of type 2 diabetes
Ruis C, Biessels GJ, Gorter KJ, van den Donk M, Kappelle LJ, Rutten GE
Diabetes Care. 2009;32(7):1261-1265 |
| • |
Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study
Kramer CK, von Mühlen D, Jassal SK, Barrett-Connor E
Diabetes Care. 2009;32(7):1272-1273. |
| • |
Low-grade chronic inflammation in the relationship between insulin sensitivity and cardiovascular disease (RISC) population: associations with insulin resistance and cardiometabolic risk profile
de Rooij SR, Nijpels G, Nilsson PM, et al, for the Relationship Between Insulin Sensitivity and Cardiovascular Disease (RISC) Investigators
Diabetes Care. 2009;32(7):1295-1301 |
|
